What is K103N mutation?
K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility. 103R. Other. K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.
What is M184V mutation?
“M184V” is the shorthand for methionine replacing valine at position 184 in reverse transcriptase. It is by far the most commonly encountered nucleoside reverse transcriptase inhibitor (NRTI) mutation after failure with regimens containing lamivudine (3TC) or emtricitabine (FTC).
Which medication causes K103N mutation?
Multiple studies of EFV administered to treatment-naive patients in combination with tenofovir, stavudine (d4T) or zidovudine (ZDV) and in combination with lamivudine or emtricitabine have shown that the NNRTI resistance mutations – primarily K103N and Y181C –are the most common mutations associated with virological …
What is NNRTI?
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind to and block HIV reverse transcriptase (an HIV enzyme). HIV uses reverse transcriptase to convert its RNA into DNA (reverse transcription). Blocking reverse transcriptase and reverse transcription prevents HIV from replicating.
Which of the following belongs to class Nnrti?
Following are the FDA-approved individual NNRTIs that are currently part of antiretroviral therapy for HIV infection; common side effects are listed.
- Delavirdine (Rescriptor)
- Efavirenz (Sustiva)
- Etravirine (Intelence)
- Nevirapine (Viramune, Viramune XR)
- Rilpivirine (Edurant)
- Doravirine (Pifeltro)
What are examples of Nnrti?
What are the FDA-approved NNRTIs and their side effects?
- Delavirdine (Rescriptor)
- Efavirenz (Sustiva)
- Etravirine (Intelence)
- Nevirapine (Viramune, Viramune XR)
- Rilpivirine (Edurant)
- Doravirine (Pifeltro)
What is the difference between v179d and v179e?
V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV.
What is the difference between the v179i and v179l mutations?
V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility. V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs.
What is the pathophysiology of the variablev90i mutation?
V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility.